Ajanta Pharma Intrinsic Value
Ajanta Pharma (AJANTPHARM) median intrinsic value is ₹3032.00 from 9 valuation models (range ₹906–₹6286), vs current price ₹3020.80 — +0.4% upside (Trading Near Calculated Value), margin of safety 0.4%. Also explore Ajanta Pharma share price performance to track price trends across different timeframes.
AJANTPHARM Valuation Methods Summary — DCF, Graham Number & P/E
Ajanta Pharma intrinsic value across 9 models vs current price ₹3020.80 — upside/downside and value range per method. For current market price and key ratios, visit Ajanta Pharma stock price NSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1878.80 | ₹1503.04 - ₹2254.56 | -37.8% | EPS: ₹85.40, Sector P/E: 22x |
| Book Value Method | asset | ₹3032.00 | ₹2728.80 - ₹3335.20 | +0.4% | Book Value/Share: ₹1516.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹4745.60 | ₹4271.04 - ₹5220.16 | +57.1% | Revenue/Share: ₹2372.80, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹6041.60 | ₹5437.44 - ₹6645.76 | +100.0% | EBITDA: ₹1580.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹6286.37 | ₹5029.10 - ₹7543.64 | +108.1% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹906.24 | ₹815.62 - ₹996.86 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1319.43 | ₹1187.49 - ₹1451.37 | -56.3% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹6041.60 | ₹5437.44 - ₹6645.76 | +100.0% | ROE: 28.2%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹1706.75 | ₹1536.08 - ₹1877.43 | -43.5% | EPS: ₹85.40, BVPS: ₹1516.00 |
AJANTPHARM Intrinsic Value vs Market Price — All Valuation Models
Ajanta Pharma fair value range ₹906–₹6286 vs current market price ₹3020.80 across 9 valuation models. Browse Ajanta Pharma financial data for revenue, profit, balance sheet and cash flow data.
AJANTPHARM Intrinsic Value Analysis — Undervalued or Overvalued?
Ajanta Pharma median intrinsic value ₹3032.00, current price ₹3020.80 — Trading Near Calculated Value by 0.4%, margin of safety 0.4%.
What is the intrinsic value of AJANTPHARM?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Ajanta Pharma (AJANTPHARM) is ₹3032.00 (median value). With the current market price of ₹3020.80, this represents a +0.4% variance from our estimated fair value.
The valuation range spans from ₹906.24 to ₹6286.37, indicating ₹906.24 - ₹6286.37.
Is AJANTPHARM undervalued or overvalued?
Based on our multi-method analysis, Ajanta Pharma (AJANTPHARM) appears to be trading near calculated value by approximately 0.4%.
AJANTPHARM Financial Health — Key Ratios vs Industry Benchmarks
Ajanta Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 12.41 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 28.2% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 23.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.18x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
AJANTPHARM Cash Flow Quality — Operating & Free Cash Flow
Ajanta Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1,157 Cr | ₹969 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹785 Cr | ₹785 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹792 Cr | ₹512 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹562 Cr | ₹525 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹576 Cr | ₹435 Cr | Positive Free Cash Flow | 8/10 |